Additionally, Pei et al. demonstrated that the STAT3 inhibitor HJC0152 (i.t., 30 μg) also enhanced the treatment effect of the STING agonist c-di-AM (PS)2 (i.t., 10 μg), leading to significant tumor rejection in a 4 T1 breast cancer model [157]. This evidence concerns the gene STING1 and neoplasm.